Summary by Moomoo AI
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINROI PHARMACEUTICALS) SUBMITTED ITS LATEST SECURITIES MONTH CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 2, 2024, REPORTING THE CHANGES IN THE COMPANY'S SHARES FOR THE YEAR ENDED MARCH 31, 2024. The report shows that Novi Pharmaceuticals' regulary/registered share capital and issued shares remained unchanged during the reporting period at 3,000,000,000 shares with a face value of HK$0.05 per share and a total share capital of HK$150,000,000. In addition, under the share option plan adopted on October 25, 2013, the Company did not exercise new stock options during the reporting month, and the number of outstanding share options was 143,200,000, with no funds received as a result of the exercise of the options. Company Secretary Wu Zhisheng confirmed that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.